CA-PONY.AI
7.3.2024 08:55:29 CET | Business Wire | Press release
Pony.ai, a leading global autonomous mobility company, held a Memorandum of Understanding (MoU) signing ceremony today with the Government of the Grand Duchy of Luxembourg (“The Government”) to advance the development of autonomous mobility in Luxembourg. The MoU was signed by Pony.ai Co-Founder and CEO Dr. James Peng and Luxembourg’s Minister of the Economy Lex Delles. This MoU represents a collaborative partnership between Luxembourg and Pony.ai, with the objective of fostering the research, development, and deployment of autonomous vehicles in Luxembourg.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240306928526/en/
Delegation from the Government of the Grand Duchy of Luxembourg visits Pony.ai’s office in Fremont, California, March 6, 2024 (Photo: Business Wire)
As a global leader in innovation and technology, Luxembourg presents an excellent opportunity for Pony.ai to further develop its leading autonomous mobility technology in Europe. Pony.ai, with the support of Luxinnovation and local stakeholders, intends to set up a regional hub in Luxembourg, which will serve as a center for Pony.ai’s cutting-edge research and development of autonomous vehicle technology. Pony.ai’s Luxembourg-based hub will be pivotal in driving technological advancements and tailoring solutions for the European market. In addition, the Government and Pony.ai aim to develop a robust local network to support operational capabilities in Luxembourg. Pony.ai looks forward to building strong local partnerships to support this effort.
Pony.ai co-founder and CEO Dr. James Peng said: “As a leading global autonomous vehicle company, Pony.ai is delighted to partner with Luxembourg as we continue our global expansion. We aim to bring to this partnership our cutting-edge AV technology, comprehensive training programs, and a commitment to establish a regional hub in Luxembourg as we continue our global expansion.”
Luxembourg Minister of the Economy Lex Delles said: “The intelligent mobility sector is one of our priorities with regard to the diversification of Luxembourg’s economy. Our aim is to make the Grand Duchy a pioneer in the field of autonomous driving on a European scale. As such, I am very pleased with the signature of an MoU with Pony.ai, a leader in autonomous mobility technologies and services. The signature today formalizes our collaboration and is an important step towards creating a synergy between the technical expertise of Pony.ai and the Luxembourg government's political strategy. The latter aims to promote research and technological development, job creation and sustainable economic growth.”
Pony.ai is a leader in autonomous mobility and in the commercialization of autonomous driving, operating Robotaxi, Robotruck and Personally Owned Vehicle (POV) business units, developing the safest autonomous driving capabilities on a global scale. Pony.ai is excited to continue its expansion into Luxembourg and the European market. For the past year, Pony.ai has engaged in detailed conversations surrounding robotaxi deployment use cases and opportunities with local stakeholders in Luxembourg and believes the country is an exciting and innovative region to introduce Pony.ai’s leading autonomous vehicles.
About Pony.ai
Leading global autonomous driving company Pony.ai, Inc. (“Pony.ai”) is pursuing an ambitious vision for autonomous mobility. We aim to bring safe, sustainable, and accessible mobility to the entire world. We believe that autonomous technology can make our roads exponentially safer for travelers. Founded in late 2016, Pony.ai has been a pioneer in extending autonomous mobility technologies and services at a rapidly expanding footprint of sites around the world. Pony.ai has formed partnerships with leading OEMs, including Toyota, SAIC, SANY, FAW Group, GAC Group, etc. To date, Pony.ai has driven over 30 million autonomous testing and operation kilometers (over 18.6 million miles) on open roads worldwide.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306928526/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom